Patents Examined by Sudhakar Katakam
  • Patent number: 10208074
    Abstract: Disclosed embodiments concern novel interleukin receptor associated kinases (IRAK) inhibitors and compositions comprising such inhibitors. Also disclosed are methods of making and using the compounds and compositions. The disclosed compounds and/or compositions may be used to treat or prevent an IRAK-associated disease or condition.
    Type: Grant
    Filed: March 22, 2018
    Date of Patent: February 19, 2019
    Assignee: Rigel Pharmaceuticals, Inc.
    Inventors: Ryan Kelley, Hui Li, Thilo Heckrodt, Yan Chen, Darren McMurtrie, Kin Tso, Vanessa Taylor, Rajinder Singh, Rose Yen, Jack Maung
  • Patent number: 10208046
    Abstract: The present invention provides a compound having a cholinergic muscarinic M1 receptor positive allosteric modulator activity, which may be useful as medicaments such as a prophylactic or therapeutic drug for Alzheimer's disease, schizophrenia, pain, sleep disorder, Parkinson's disease dementia, dementia with Lewy bodies and the like, and the like. The present invention relates to a compound represented by the formula (I) wherein ring A is an optionally substituted 5- or 6-membered ring; R is a C1-6 alkyl group substituted by 1 to 5 halogen atoms; and X is —CH? or —N?, or a salt thereof.
    Type: Grant
    Filed: May 15, 2015
    Date of Patent: February 19, 2019
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Takahiro Sugimoto, Kenichiro Shimokawa, Takuto Kojima, Hiroki Sakamoto, Ikuo Fujimori, Minoru Nakamura, Masami Yamada, Masataka Murakami, Makoto Kamata, Shinkichi Suzuki
  • Patent number: 10188650
    Abstract: Provided herein is technology relating to treatment of neurological disorders and particularly, but not exclusively, to methods and compositions for treating neurological disorders caused by aberrant and/or dysregulated expression and/or activity of Down syndrome cell adhesion molecule (Dscam) with agents that modulate physiological components associated with the functions and/or dysfunctions of Dscam, e.g., physiological components that can be modulated to counteract aberrant Dscam expression and/or activity such as Abelson murine leukemia viral oncogene homolog 1 kinase.
    Type: Grant
    Filed: December 23, 2014
    Date of Patent: January 29, 2019
    Assignee: THE REGENTS OF THE UNIVERSITY OF MICHIGAN
    Inventors: Bing Ye, Jung Hwan Kim, Gabriella Sterne
  • Patent number: 10188695
    Abstract: The present invention relates to a calcineurin inhibitor for use in the treatment of a lesional vestibular disorder.
    Type: Grant
    Filed: February 22, 2013
    Date of Patent: January 29, 2019
    Assignees: Sensorion, INSERM
    Inventor: Jonas Dyhrfjeld-Johnsen
  • Patent number: 10188659
    Abstract: The present invention provides compounds acting as Insulin/IGF signaling modulators useful in the treatment of neurodegenerative diseases and disorders. The invention provides pharmaceutical compositions including such compounds, and methods of using these compounds and compositions for the treatment of neurodegenerative diseases, in particular neurodegenerative diseases caused by proteotoxicity such as Alzheimer's disease.
    Type: Grant
    Filed: August 24, 2017
    Date of Patent: January 29, 2019
    Assignee: YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM, LTD.
    Inventors: Hadas Reuveni, Ehud Cohen, Alexander Levitzki, Shmuel Ben-Sasson
  • Patent number: 10188759
    Abstract: The invention described herein relates to conjugates and compositions for imaging, diagnosing, and/or monitoring diseases using radionuclide-based imaging. In particular, the invention described herein relates to conjugates and compositions for imaging, diagnosing, and/or monitoring diseases using positron emission tomography.
    Type: Grant
    Filed: January 6, 2016
    Date of Patent: January 29, 2019
    Assignee: Endocyte, Inc.
    Inventors: Iontcho R. Vlahov, Christopher P. Leamon, Hari Krishna R. Santhapuram
  • Patent number: 10179136
    Abstract: Pharmaceutical compositions and methods for inducing conscious sedation using such compositions are described, the compositions including a benzodiazepine-based compound, a NMDA antagonist, and optionally a ?-blocker, antiemetic, an NSAID, and/or an antihistamine medication. Methods for fabricating the compositions and using them for anesthesiological applications are also described.
    Type: Grant
    Filed: February 23, 2018
    Date of Patent: January 15, 2019
    Assignee: Imprimis Pharmaceuticals, Inc.
    Inventors: John Berdahl, William F. Wiley, Dennis Elias Saadeh
  • Patent number: 10179120
    Abstract: The present invention relates to a dosage regimen of ST10 (ferric trimaltol) for the treatment of patients suffering from iron deficiency with or without anaemia. Specifically the invention relates to the treatment of patients with 30 mg ST10 twice daily.
    Type: Grant
    Filed: January 6, 2015
    Date of Patent: January 15, 2019
    Assignee: Iron Therapeutics Holdings AG
    Inventors: Christian Schweiger, Carl Andrew Sterritt, Julian David Howell
  • Patent number: 10172819
    Abstract: Omega-3 compositions, dosage forms, and methods of use are disclosed herein. The omega-3 compositions and dosage forms disclosed herein may comprise DHA and EPA. The omega-3 compositions and dosage forms disclosed herein may comprise re-esterified triglycerides. Methods of treatment using the compositions and dosage forms are also disclosed.
    Type: Grant
    Filed: June 29, 2018
    Date of Patent: January 8, 2019
    Assignee: MARINE INGREDIENTS, LLC
    Inventors: Olav Sandnes, Bruce A. Miller, Jorn Dyerberg
  • Patent number: 10172818
    Abstract: In various embodiments, the present invention provides methods of treating and/or preventing cardiovascular-related disease and, in particular, a method of reducing or preventing small dense LDL (“sdLDL”) oxidation in a subject, the method comprising administering to the subject a pharmaceutical composition comprising eicosapentaenoic acid or a derivative thereof.
    Type: Grant
    Filed: June 16, 2015
    Date of Patent: January 8, 2019
    Assignee: Amarin Pharmaceuticals Ireland Limited
    Inventor: Richard Preston Mason
  • Patent number: 10166201
    Abstract: It discloses a compound of formula I that inhibits the activities of numerous of protein kinases involving the signaling of inflammatory cytokines, therefore, the compound can be used for treating cancers, autoimmune diseases and inflammatory diseases.
    Type: Grant
    Filed: June 29, 2017
    Date of Patent: January 1, 2019
    Assignee: RESOLVEX PHARMACEUTICALS INC.
    Inventors: Liren Tang, Junling Zhang, Tao Guo, Michael Patrick Allen Lyle
  • Patent number: 10167272
    Abstract: This invention relates to compounds that are agonists of the muscarinic M1 receptor and/or M4 receptor and which are useful in the treatment of muscarinic M1/M4 receptor mediated diseases. Also provided are pharmaceutical compositions containing the compounds and the therapeutic uses of the compounds. Compounds include those according to formula (1a) or a salt thereof, wherein p, q, r, s, Q, R3 and R4 are as defined herein.
    Type: Grant
    Filed: February 1, 2018
    Date of Patent: January 1, 2019
    Assignee: Heptares Therapeutics Limited
    Inventors: Giles Albert Brown, Miles Stuart Congreve, Mark Pickworth, Benjamin Gerald Tehan
  • Patent number: 10167250
    Abstract: The present invention relates to a process for preparation of 2-(trihalomethyl) benzamide.
    Type: Grant
    Filed: June 16, 2015
    Date of Patent: January 1, 2019
    Assignee: SRF Limited
    Inventors: Surender Dhingra, Kundan Singh Shekhawat, Satish Kumar, Kapil Kumar, Rajdeep Anand
  • Patent number: 10166240
    Abstract: Pharmaceutical compositions and methods for inducing conscious sedation using such compositions are described, the compositions including a benzodiazepine-based compound, a NMDA antagonist, and optionally a ?-blocker, antiemetic, an NSAID, and/or an antihistamine medication. Methods for fabricating the compositions and using them for anesthesiological applications are also described.
    Type: Grant
    Filed: February 23, 2018
    Date of Patent: January 1, 2019
    Assignee: Imprimis Pharmaceuticals, Inc.
    Inventors: John Berdahl, William F. Wiley, Dennis Elias Saadeh
  • Patent number: 10159683
    Abstract: The present embodiments provide for a treatment regimen and use of a short-term sustained release liquid formulation of dexamethasone in citrate, wherein a single administration of a minute dosage form into the anterior chamber of the eye provides for anti-inflammatory therapy following cataract surgery.
    Type: Grant
    Filed: June 26, 2018
    Date of Patent: December 25, 2018
    Assignee: ICON BIOSCIENCE, INC.
    Inventors: Vernon G. Wong, William S. White, Mae W. Hu, Glenn T. Huang, Faina Karasina
  • Patent number: 10155716
    Abstract: The present invention provides amine salts of the prostacyclin analogue of Formula I and processes for generating these amine salts.
    Type: Grant
    Filed: December 22, 2017
    Date of Patent: December 18, 2018
    Assignee: Cayman Chemical Company Incorporated
    Inventors: Gilles Chambournier, Gregory William Endres, Kirk William Hering, Victor Fedij, Hussein Mahmoud Mahmoud
  • Patent number: 10150729
    Abstract: New tranilast complexes and new tranilast cocrystals are disclosed. These include a 1:1 tranilast nicotinamide complex, a 1:1 tranilast nicotinamide cocrystal, a 1:1 tranilast saccharin complex, a 1:1 tranilast saccharin cocrystal, a 1:1 tranilast gentisic acid complex, a 1:1 tranilast gentisic acid cocrystal, a 1:1 tranilast salicylic acid complex, a 1:1 tranilast salicylic acid cocrystal, a 1:1 tranilast urea complex, a 1:1 tranilast urea cocrystal, a 1:1 tranilast 4-aminobenzoic acid complex, a 1:1 tranilast 4-aminobenzoic acid cocrystal, a 1:1 tranilast 2,4-dihydroxybenzoic acid complex and a 1:1 tranilast 2,4-dihydroxybenzoic acid cocrystal. Also disclosed are pharmaceutical compositions containing a tranilast complex or cocrystal of the invention and a pharmaceutically acceptable carrier. Methods of treatment using the tranilast complexes and cocrystals as well as the pharmaceutical compositions are disclosed.
    Type: Grant
    Filed: October 26, 2017
    Date of Patent: December 11, 2018
    Assignee: NUFORMIX TECHNOLOGIES LIMITED
    Inventors: Joanne Holland, Christopher Frampton
  • Patent number: 10143680
    Abstract: The present invention relates to pharmaceutical dosage forms for oral administration comprising the drug substance 4-[(5R)-6,7-dihydro-5H-pyrrolo[1,2-c]imidazol-5-yl]-3-fluorobenzonitrile or any pharmaceutically acceptable salt thereof and to processes of making said solid pharmaceutical dosage forms.
    Type: Grant
    Filed: July 6, 2015
    Date of Patent: December 4, 2018
    Assignee: Novartis AG
    Inventors: Stefania Beato, Peggy Quinton
  • Patent number: 10143668
    Abstract: The present invention relates to hydroxy-substituted amino and ammonium derivatives, in particular the compounds of formula (1) or (2), and their medical use, including their use in the treatment, prevention or amelioration of an inflammatory, autoimmune and/or allergic disorder, or a proliferative, neoplastic or dysplastic disease or disorder.
    Type: Grant
    Filed: February 17, 2017
    Date of Patent: December 4, 2018
    Assignee: GRI BIO, INC.
    Inventors: Georg Schlechtingen, Hans-Joachim Knolker, Tim Friedrichson, Gary Jennings, Tobias Braxmeier
  • Patent number: 10137102
    Abstract: The present invention relates to medicaments based on oligomeric forms of 3-hydroxybutyrate, particularly 3-hydroxybutyrate methyl ester dimer (1) and trimer (2), especially for use in treating, preventing and/or inhibiting development of a disorder or condition related to oxidative stress. The present invention relates also to the use of these molecules as antioxidants, and to a method for increasing proliferation and viability of plant cells in the aid of molecules 1 and 2.
    Type: Grant
    Filed: July 21, 2015
    Date of Patent: November 27, 2018
    Inventors: Anna Maria Pirttilä, Janne Koskimäki, Sampo Mattila, Marena Kajula, Juho Hokkanen, Bruce Campbell